9.9 billion Swiss francs in core research and development
expenditure in 2016 makes Roche one of the most
research focused companies worldwide.
Our 120 year heritage and a stable shareholder structure
ensure a long-term view and a strong and stable
commitment to researching and developing novel
treatments in the areas of oncology, immunology,
infectious diseases, ophthalmology and neuroscience
in order to improve the lives of patients all over the world.
Because it’s not just a job.
It’s a responsibility.
A big one.
The next step is yours.
Make a difference.